This segment focuses on the research and development of oral biologics for the treatment of inflammatory diseases, including psoriasis, atopic dermatitis, and the hyperinflammatory response associated with COVID-19. Research and development activities include the development of EDP1815, EDP1867, and EDP2939. These candidates utilize whole-microbe, inactivated, and extracellular vesicle approaches, respectively. The technologies employed involve the use of naturally occurring bacteria and their components to modulate the immune system via the gut-immune axis. The patient impact is aimed at providing effective and safe treatments for chronic inflammatory conditions, improving quality of life, and addressing unmet medical needs. Market positioning is based on a novel approach to drug delivery and immune modulation, offering potential advantages over traditional therapies. Future opportunities include expanding the pipeline to address additional inflammatory conditions and exploring combination therapies. Clinical trials are a key aspect of this segment, with regulatory compliance and FDA approval being critical for commercialization. Partnerships with organizations like Abdul Latif Jameel Health are crucial for global market access and commercialization.

This segment is dedicated to the development of EDP1908, a product candidate for oncology. Research and development efforts are focused on leveraging the company's platform to create oral biologics that can target and treat various cancers. The technologies used involve the application of the company's platform to develop novel therapeutic approaches. The therapeutic area covered is oncology, with the aim of providing new treatment options for cancer patients. The patient impact is focused on improving cancer treatment outcomes and providing safer and more effective therapies. Market positioning is based on the development of innovative oncology treatments. Future opportunities include expanding the oncology pipeline and exploring combination therapies. Clinical trials and regulatory approvals are essential for the commercialization of oncology products. The company may seek partnerships to accelerate the development and commercialization of its oncology product candidates.